Demographic features, presentation, management, and outcome EBV+ LBCLs in young patients
| Characteristics . | THRLBCL–like . | GZL . | DLBCL-NOS . | Total . |
|---|---|---|---|---|
| Total | 36 | 7 | 3 | 46 |
| Age median (range) | 24 (4-45) | 23 (13-42) | 27 (22-33) | 23 (4-45) |
| Male/female | 32/4 (8:1) | 3/4 | 1/2 | 36/10 |
| Involved sites, n | 36 | 7 | 3 | 46 |
| Nodal, n (%) | 31 (86) | 7* (100) | 3 (100) | 41 (89) |
| Nodal and extranodal, n (%) | 5 (14) | 0 (0) | 0 (0) | 5 (11) |
| Extent of disease, n | 35 | 7 | 3 | 45 |
| Localized, n (%) | 9 (26) | 3 (43) | 2 (67) | 14 (31) |
| Two sites, n (%) | 8 (23) | 1 (14) | 0 (0) | 9 (20) |
| Multiple sites (>2 and ≤5), n (%) | 3 (8) | 2 (29) | 0 (0) | 5 (11) |
| Generalized, n (%) | 15 (43) | 1 (14) | 1 (33) | 17 (38) |
| B symptoms, n | 32 | 7 | 3 | 42 |
| Present, n (%) | 15 (47) | 6 (86) | 1 (33) | 22 (52) |
| Absent, n (%) | 17 (53) | 1 (14) | 2 (67) | 20 (48) |
| LDH, n | 32 | 5 | 2 | 39 |
| Normal, n (%) | 10 (31) | 2 (40) | 1 (50) | 13 (33) |
| Elevated, n (%) | 22 (69) | 3 (60) | 1 (50) | 26 (67) |
| CBC counts, n | 31 | 5 | 2 | 38 |
| Normal, n (%) | 18 (58) | 3 (60) | 0 (0) | 21 (55) |
| Abnormal, n (%) | 13 (42) | 2 (40) | 2 (100) | 17 (45) |
| IPI score, n | 15 | 3 | 1 | 19 |
| L+LI (0-2), n (%) | 9 (60) | 2 (67) | 1 (100) | 12 (63) |
| HI+H (3-4), n (%) | 6 (40) | 1 (33) | 0 (0) | 7 (37) |
| Clinical stage, n | 30 | 4 | 2 | 36 |
| I + II, n (%) | 12 (40) | 3 (75) | 1 (50) | 16 (44) |
| III + IV, n (%) | 18 (60) | 1 (25) | 1 (50) | 20 (56) |
| Management, n | 32 | 5 | 2 | 39 |
| No treatment | 1 (3) | 0 (0) | 0 (0) | 1 (3) |
| Immunochemotherapy, n (%) | 19† (60) | 2 (40) | 1 (50) | 22 (56) |
| Immunochemotherapy + radiotherapy, n (%) | 3 (9) | 1 (20) | 0 (0) | 4 (10) |
| Chemotherapy, n (%) | 3 (9) | 0 (0) | 0 (0) | 3 (8) |
| Chemotherapy + radiotherapy, n (%) | 2 (6) | 1 (20) | 1 (50) | 4 (10) |
| Immunochemotherapy + BMT, n (%) | 4 (13) | 1 (20) | 0 (0) | 5‡ (13) |
| Outcome, n | 31 | 6 | 2 | 39 |
| Alive, NoD/CR, n (%) | 27 (87) | 4 (66) | 1 (50) | 32 (82) |
| Alive, AwD, n (%) | 3 (10) | 1 (17) | 0 (0) | 4 (10) |
| DOD, n (%) | 1 (3) | 1 (17) | 1 (50) | 3 (8) |
| Median (range) follow-up, mo | 24 (4-96) | 18.5 (6-58) | 13.5 (7-20) | 22 (4-96) |
| Characteristics . | THRLBCL–like . | GZL . | DLBCL-NOS . | Total . |
|---|---|---|---|---|
| Total | 36 | 7 | 3 | 46 |
| Age median (range) | 24 (4-45) | 23 (13-42) | 27 (22-33) | 23 (4-45) |
| Male/female | 32/4 (8:1) | 3/4 | 1/2 | 36/10 |
| Involved sites, n | 36 | 7 | 3 | 46 |
| Nodal, n (%) | 31 (86) | 7* (100) | 3 (100) | 41 (89) |
| Nodal and extranodal, n (%) | 5 (14) | 0 (0) | 0 (0) | 5 (11) |
| Extent of disease, n | 35 | 7 | 3 | 45 |
| Localized, n (%) | 9 (26) | 3 (43) | 2 (67) | 14 (31) |
| Two sites, n (%) | 8 (23) | 1 (14) | 0 (0) | 9 (20) |
| Multiple sites (>2 and ≤5), n (%) | 3 (8) | 2 (29) | 0 (0) | 5 (11) |
| Generalized, n (%) | 15 (43) | 1 (14) | 1 (33) | 17 (38) |
| B symptoms, n | 32 | 7 | 3 | 42 |
| Present, n (%) | 15 (47) | 6 (86) | 1 (33) | 22 (52) |
| Absent, n (%) | 17 (53) | 1 (14) | 2 (67) | 20 (48) |
| LDH, n | 32 | 5 | 2 | 39 |
| Normal, n (%) | 10 (31) | 2 (40) | 1 (50) | 13 (33) |
| Elevated, n (%) | 22 (69) | 3 (60) | 1 (50) | 26 (67) |
| CBC counts, n | 31 | 5 | 2 | 38 |
| Normal, n (%) | 18 (58) | 3 (60) | 0 (0) | 21 (55) |
| Abnormal, n (%) | 13 (42) | 2 (40) | 2 (100) | 17 (45) |
| IPI score, n | 15 | 3 | 1 | 19 |
| L+LI (0-2), n (%) | 9 (60) | 2 (67) | 1 (100) | 12 (63) |
| HI+H (3-4), n (%) | 6 (40) | 1 (33) | 0 (0) | 7 (37) |
| Clinical stage, n | 30 | 4 | 2 | 36 |
| I + II, n (%) | 12 (40) | 3 (75) | 1 (50) | 16 (44) |
| III + IV, n (%) | 18 (60) | 1 (25) | 1 (50) | 20 (56) |
| Management, n | 32 | 5 | 2 | 39 |
| No treatment | 1 (3) | 0 (0) | 0 (0) | 1 (3) |
| Immunochemotherapy, n (%) | 19† (60) | 2 (40) | 1 (50) | 22 (56) |
| Immunochemotherapy + radiotherapy, n (%) | 3 (9) | 1 (20) | 0 (0) | 4 (10) |
| Chemotherapy, n (%) | 3 (9) | 0 (0) | 0 (0) | 3 (8) |
| Chemotherapy + radiotherapy, n (%) | 2 (6) | 1 (20) | 1 (50) | 4 (10) |
| Immunochemotherapy + BMT, n (%) | 4 (13) | 1 (20) | 0 (0) | 5‡ (13) |
| Outcome, n | 31 | 6 | 2 | 39 |
| Alive, NoD/CR, n (%) | 27 (87) | 4 (66) | 1 (50) | 32 (82) |
| Alive, AwD, n (%) | 3 (10) | 1 (17) | 0 (0) | 4 (10) |
| DOD, n (%) | 1 (3) | 1 (17) | 1 (50) | 3 (8) |
| Median (range) follow-up, mo | 24 (4-96) | 18.5 (6-58) | 13.5 (7-20) | 22 (4-96) |